Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Xenograft-based platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma.

Zhao SG, Yu M, Spratt DE, Chang SL, Feng FY, Kim MM, Speers CW, Carlson BL, Mladek AC, Lawrence TS, Sarkaria JN, Wahl DR.

Neuro Oncol. 2019 May 23. pii: noz090. doi: 10.1093/neuonc/noz090. [Epub ahead of print]

PMID:
31121035
2.

Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma.

Randall EC, Emdal KB, Laramy JK, Kim M, Roos A, Calligaris D, Regan MS, Gupta SK, Mladek AC, Carlson BL, Johnson AJ, Lu FK, Xie XS, Joughin BA, Reddy RJ, Peng S, Abdelmoula WM, Jackson PR, Kolluri A, Kellersberger KA, Agar JN, Lauffenburger DA, Swanson KR, Tran NL, Elmquist WF, White FM, Sarkaria JN, Agar NYR.

Nat Commun. 2018 Nov 21;9(1):4904. doi: 10.1038/s41467-018-07334-3.

3.

Quantifying the setup uncertainty of a stereotactic murine micro-image guided radiation therapy system.

Walb MC, Carlson BL, Sarkaria JN, Tryggestad EJ.

Br J Radiol. 2019 Mar;92(1095):20180487. doi: 10.1259/bjr.20180487. Epub 2018 Nov 14.

PMID:
30299986
4.

Past role and future outlook of the Conservation Reserve Program for supporting honey bees in the Great Plains.

Otto CRV, Zheng H, Gallant AL, Iovanna R, Carlson BL, Smart MD, Hyberg S.

Proc Natl Acad Sci U S A. 2018 Jul 17;115(29):7629-7634. doi: 10.1073/pnas.1800057115. Epub 2018 Jul 2. Erratum in: Proc Natl Acad Sci U S A. 2018 Aug 7;115(32):E7651.

5.

Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma.

Kizilbash SH, Gupta SK, Chang K, Kawashima R, Parrish KE, Carlson BL, Bakken KK, Mladek AC, Schroeder MA, Decker PA, Kitange GJ, Shen Y, Feng Y, Protter AA, Elmquist WF, Sarkaria JN.

Mol Cancer Ther. 2017 Dec;16(12):2735-2746. doi: 10.1158/1535-7163.MCT-17-0365. Epub 2017 Sep 25.

6.

CD90 Expression Controls Migration and Predicts Dasatinib Response in Glioblastoma.

Avril T, Etcheverry A, Pineau R, Obacz J, Jegou G, Jouan F, Le Reste PJ, Hatami M, Colen RR, Carlson BL, Decker PA, Sarkaria JN, Vauléon E, Chiforeanu DC, Clavreul A, Mosser J, Chevet E, Quillien V.

Clin Cancer Res. 2017 Dec 1;23(23):7360-7374. doi: 10.1158/1078-0432.CCR-17-1549. Epub 2017 Sep 22.

7.

Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma.

Laramy JK, Kim M, Gupta SK, Parrish KE, Zhang S, Bakken KK, Carlson BL, Mladek AC, Ma DJ, Sarkaria JN, Elmquist WF.

J Pharmacol Exp Ther. 2017 Nov;363(2):136-147. doi: 10.1124/jpet.117.243477. Epub 2017 Aug 28.

8.

Land-use change reduces habitat suitability for supporting managed honey bee colonies in the Northern Great Plains.

Otto CR, Roth CL, Carlson BL, Smart MD.

Proc Natl Acad Sci U S A. 2016 Sep 13;113(37):10430-5. doi: 10.1073/pnas.1603481113. Epub 2016 Aug 29.

9.

Retinoblastoma Binding Protein 4 Modulates Temozolomide Sensitivity in Glioblastoma by Regulating DNA Repair Proteins.

Kitange GJ, Mladek AC, Schroeder MA, Pokorny JC, Carlson BL, Zhang Y, Nair AA, Lee JH, Yan H, Decker PA, Zhang Z, Sarkaria JN.

Cell Rep. 2016 Mar 22;14(11):2587-98. doi: 10.1016/j.celrep.2016.02.045. Epub 2016 Mar 10.

10.

Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma.

Gupta SK, Kizilbash SH, Carlson BL, Mladek AC, Boakye-Agyeman F, Bakken KK, Pokorny JL, Schroeder MA, Decker PA, Cen L, Eckel-Passow JE, Sarkar G, Ballman KV, Reid JM, Jenkins RB, Verhaak RG, Sulman EP, Kitange GJ, Sarkaria JN.

J Natl Cancer Inst. 2015 Nov 27;108(5). pii: djv369. doi: 10.1093/jnci/djv369. Print 2016 May.

11.

Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases.

Vaidhyanathan S, Wilken-Resman B, Ma DJ, Parrish KE, Mittapalli RK, Carlson BL, Sarkaria JN, Elmquist WF.

J Pharmacol Exp Ther. 2016 Feb;356(2):251-9. doi: 10.1124/jpet.115.229393. Epub 2015 Nov 24.

12.

Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System.

Parrish KE, Cen L, Murray J, Calligaris D, Kizilbash S, Mittapalli RK, Carlson BL, Schroeder MA, Sludden J, Boddy AV, Agar NY, Curtin NJ, Elmquist WF, Sarkaria JN.

Mol Cancer Ther. 2015 Dec;14(12):2735-43. doi: 10.1158/1535-7163.MCT-15-0553. Epub 2015 Oct 5.

13.

Effective Treatment of Established GL261 Murine Gliomas through Picornavirus Vaccination-Enhanced Tumor Antigen-Specific CD8+ T Cell Responses.

Renner DN, Jin F, Litterman AJ, Balgeman AJ, Hanson LM, Gamez JD, Chae M, Carlson BL, Sarkaria JN, Parney IF, Ohlfest JR, Pirko I, Pavelko KD, Johnson AJ.

PLoS One. 2015 May 1;10(5):e0125565. doi: 10.1371/journal.pone.0125565. eCollection 2015.

14.

The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma.

Pokorny JL, Calligaris D, Gupta SK, Iyekegbe DO Jr, Mueller D, Bakken KK, Carlson BL, Schroeder MA, Evans DL, Lou Z, Decker PA, Eckel-Passow JE, Pucci V, Ma B, Shumway SD, Elmquist WF, Agar NY, Sarkaria JN.

Clin Cancer Res. 2015 Apr 15;21(8):1916-24. doi: 10.1158/1078-0432.CCR-14-2588. Epub 2015 Jan 21.

15.

The National Children's Study 2014: commentary on a recent National Research Council/Institute of Medicine Report.

McCormick MC, Baker DB, Biemer PP, Carlson BL, Diez Roux AV, Lesser VM, McLanahan SS, Saade GR, Stokes SL, Trasande L, Duncan GJ.

Acad Pediatr. 2014 Nov-Dec;14(6):545-6. doi: 10.1016/j.acap.2014.08.008. Epub 2014 Oct 30. No abstract available.

PMID:
25439149
16.

Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.

Gupta SK, Mladek AC, Carlson BL, Boakye-Agyeman F, Bakken KK, Kizilbash SH, Schroeder MA, Reid J, Sarkaria JN.

Clin Cancer Res. 2014 Jul 15;20(14):3730-41. doi: 10.1158/1078-0432.CCR-13-3446. Epub 2014 May 16.

17.

Sulfatase-activated fluorophores for rapid discrimination of mycobacterial species and strains.

Beatty KE, Williams M, Carlson BL, Swarts BM, Warren RM, van Helden PD, Bertozzi CR.

Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):12911-6. doi: 10.1073/pnas.1222041110. Epub 2013 Jul 22.

18.

Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.

Cen L, Carlson BL, Pokorny JL, Mladek AC, Grogan PT, Schroeder MA, Decker PA, Anderson SK, Giannini C, Wu W, Ballman KV, Kitange GJ, Sarkaria JN.

Neuro Oncol. 2013 Jun;15(6):735-46. doi: 10.1093/neuonc/not010. Epub 2013 Mar 10.

19.

Targeting Src family kinases inhibits bevacizumab-induced glioma cell invasion.

Huveldt D, Lewis-Tuffin LJ, Carlson BL, Schroeder MA, Rodriguez F, Giannini C, Galanis E, Sarkaria JN, Anastasiadis PZ.

PLoS One. 2013;8(2):e56505. doi: 10.1371/journal.pone.0056505. Epub 2013 Feb 14.

20.

p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.

Cen L, Carlson BL, Schroeder MA, Ostrem JL, Kitange GJ, Mladek AC, Fink SR, Decker PA, Wu W, Kim JS, Waldman T, Jenkins RB, Sarkaria JN.

Neuro Oncol. 2012 Jul;14(7):870-81. doi: 10.1093/neuonc/nos114. Epub 2012 Jun 18.

21.

Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts.

Kitange GJ, Mladek AC, Carlson BL, Schroeder MA, Pokorny JL, Cen L, Decker PA, Wu W, Lomberk GA, Gupta SK, Urrutia RA, Sarkaria JN.

Clin Cancer Res. 2012 Aug 1;18(15):4070-9. doi: 10.1158/1078-0432.CCR-12-0560. Epub 2012 Jun 6.

22.

Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients.

Agnihotri S, Gajadhar AS, Ternamian C, Gorlia T, Diefes KL, Mischel PS, Kelly J, McGown G, Thorncroft M, Carlson BL, Sarkaria JN, Margison GP, Aldape K, Hawkins C, Hegi M, Guha A.

J Clin Invest. 2012 Jan;122(1):253-66. doi: 10.1172/JCI59334. Epub 2011 Dec 12. Erratum in: J Clin Invest. 2012 Feb 1;122(2):782.

23.

Establishment, maintenance and in vitro and in vivo applications of primary human glioblastoma multiforme (GBM) xenograft models for translational biology studies and drug discovery.

Carlson BL, Pokorny JL, Schroeder MA, Sarkaria JN.

Curr Protoc Pharmacol. 2011 Mar;Chapter 14:Unit 14.16. doi: 10.1002/0471141755.ph1416s52.

24.

Expression of CD74 in high grade gliomas: a potential role in temozolomide resistance.

Kitange GJ, Carlson BL, Schroeder MA, Decker PA, Morlan BW, Wu W, Ballman KV, Giannini C, Sarkaria JN.

J Neurooncol. 2010 Nov;100(2):177-86. doi: 10.1007/s11060-010-0186-9. Epub 2010 May 5.

25.

Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.

Carlson BL, Grogan PT, Mladek AC, Schroeder MA, Kitange GJ, Decker PA, Giannini C, Wu W, Ballman KA, James CD, Sarkaria JN.

Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):212-9. doi: 10.1016/j.ijrobp.2009.04.026.

26.

Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice.

Schlosburg JE, Carlson BL, Ramesh D, Abdullah RA, Long JZ, Cravatt BF, Lichtman AH.

AAPS J. 2009 Jun;11(2):342-52. doi: 10.1208/s12248-009-9110-7. Epub 2009 May 9.

27.

PapA3 is an acyltransferase required for polyacyltrehalose biosynthesis in Mycobacterium tuberculosis.

Hatzios SK, Schelle MW, Holsclaw CM, Behrens CR, Botyanszki Z, Lin FL, Carlson BL, Kumar P, Leary JA, Bertozzi CR.

J Biol Chem. 2009 May 8;284(19):12745-51. doi: 10.1074/jbc.M809088200. Epub 2009 Mar 10.

28.

Intimate partner violence, health status, and health care access among women with disabilities.

Barrett KA, O'Day B, Roche A, Carlson BL.

Womens Health Issues. 2009 Mar-Apr;19(2):94-100. doi: 10.1016/j.whi.2008.10.005.

PMID:
19272559
29.

Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag.

Wu P, Shui W, Carlson BL, Hu N, Rabuka D, Lee J, Bertozzi CR.

Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3000-5. doi: 10.1073/pnas.0807820106. Epub 2009 Feb 6.

30.

Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines.

Clarke MJ, Mulligan EA, Grogan PT, Mladek AC, Carlson BL, Schroeder MA, Curtin NJ, Lou Z, Decker PA, Wu W, Plummer ER, Sarkaria JN.

Mol Cancer Ther. 2009 Feb;8(2):407-14. doi: 10.1158/1535-7163.MCT-08-0854. Epub 2009 Jan 27.

31.

Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.

Kitange GJ, Carlson BL, Mladek AC, Decker PA, Schroeder MA, Wu W, Grogan PT, Giannini C, Ballman KV, Buckner JC, James CD, Sarkaria JN.

J Neurooncol. 2009 Mar;92(1):23-31. doi: 10.1007/s11060-008-9737-8. Epub 2008 Nov 15.

32.

Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.

Kitange GJ, Carlson BL, Schroeder MA, Grogan PT, Lamont JD, Decker PA, Wu W, James CD, Sarkaria JN.

Neuro Oncol. 2009 Jun;11(3):281-91. doi: 10.1215/15228517-2008-090. Epub 2008 Oct 24.

33.

PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel.

Yang L, Clarke MJ, Carlson BL, Mladek AC, Schroeder MA, Decker P, Wu W, Kitange GJ, Grogan PT, Goble JM, Uhm J, Galanis E, Giannini C, Lane HA, James CD, Sarkaria JN.

Clin Cancer Res. 2008 Jun 15;14(12):3993-4001. doi: 10.1158/1078-0432.CCR-07-4152.

34.

Function and structure of a prokaryotic formylglycine-generating enzyme.

Carlson BL, Ballister ER, Skordalakes E, King DS, Breidenbach MA, Gilmore SA, Berger JM, Bertozzi CR.

J Biol Chem. 2008 Jul 18;283(29):20117-25. doi: 10.1074/jbc.M800217200. Epub 2008 Apr 4.

35.

Using fluorodeoxythymidine to monitor anti-EGFR inhibitor therapy in squamous cell carcinoma xenografts.

Atkinson DM, Clarke MJ, Mladek AC, Carlson BL, Trump DP, Jacobson MS, Kemp BJ, Lowe VJ, Sarkaria JN.

Head Neck. 2008 Jun;30(6):790-9. doi: 10.1002/hed.20770.

36.

Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy.

Dinca EB, Sarkaria JN, Schroeder MA, Carlson BL, Voicu R, Gupta N, Berger MS, James CD.

J Neurosurg. 2007 Sep;107(3):610-6.

PMID:
17886562
37.

Introducing genetically encoded aldehydes into proteins.

Carrico IS, Carlson BL, Bertozzi CR.

Nat Chem Biol. 2007 Jun;3(6):321-2. Epub 2007 Apr 22.

PMID:
17450134
38.

Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel.

Sarkaria JN, Yang L, Grogan PT, Kitange GJ, Carlson BL, Schroeder MA, Galanis E, Giannini C, Wu W, Dinca EB, James CD.

Mol Cancer Ther. 2007 Mar;6(3):1167-74.

39.

Effects of Cash and Counseling on personal care and well-being.

Carlson BL, Foster L, Dale SB, Brown R.

Health Serv Res. 2007 Feb;42(1 Pt 2):467-87.

40.

Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response.

Sarkaria JN, Carlson BL, Schroeder MA, Grogan P, Brown PD, Giannini C, Ballman KV, Kitange GJ, Guha A, Pandita A, James CD.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2264-71.

41.

How do hired workers fare under consumer-directed personal care?

Dale S, Brown R, Phillips B, Carlson BL.

Gerontologist. 2005 Oct;45(5):583-92.

PMID:
16199392
42.

Easing the burden of caregiving: the impact of consumer direction on primary informal caregivers in Arkansas.

Foster L, Brown R, Phillips B, Carlson BL.

Gerontologist. 2005 Aug;45(4):474-85.

PMID:
16051910
43.

Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme.

Giannini C, Sarkaria JN, Saito A, Uhm JH, Galanis E, Carlson BL, Schroeder MA, James CD.

Neuro Oncol. 2005 Apr;7(2):164-76.

44.

The effects of cash and counseling on personal care services and Medicaid costs in Arkansas.

Dale S, Brown R, Phillips B, Schore J, Carlson BL.

Health Aff (Millwood). 2003 Jul-Dec;Suppl Web Exclusives:W3-566-75.

PMID:
15506160
45.

Trehalose is required for growth of Mycobacterium smegmatis.

Woodruff PJ, Carlson BL, Siridechadilok B, Pratt MR, Senaratne RH, Mougous JD, Riley LW, Williams SJ, Bertozzi CR.

J Biol Chem. 2004 Jul 9;279(28):28835-43. Epub 2004 Apr 21.

46.

Improving the quality of Medicaid personal assistance through consumer direction.

Foster L, Brown R, Phillips B, Schore J, Carlson BL.

Health Aff (Millwood). 2003 Jan-Jun;Suppl Web Exclusives:W3-162-75.

PMID:
14527250
47.

Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy.

Eshleman JS, Carlson BL, Mladek AC, Kastner BD, Shide KL, Sarkaria JN.

Cancer Res. 2002 Dec 15;62(24):7291-7.

48.

Light-driven translocation of the protein phosphatase 2A complex regulates light/dark dephosphorylation of phosducin and rhodopsin.

Brown BM, Carlson BL, Zhu X, Lolley RN, Craft CM.

Biochemistry. 2002 Nov 19;41(46):13526-38.

PMID:
12427013
49.

Primary care of patients without insurance by community health centers.

Carlson BL, Eden J, O'Connor D, Regan J.

J Ambul Care Manage. 2001 Apr;24(2):47-59.

PMID:
11314701
50.

The amount, distribution, and timing of lifetime nursing home use.

Murtaugh CM, Kemper P, Spillman BC, Carlson BL.

Med Care. 1997 Mar;35(3):204-18.

PMID:
9071254

Supplemental Content

Loading ...
Support Center